145 related articles for article (PubMed ID: 19449195)
1. Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan.
Ohta K; Nishiki Kosaka S; Nakao Y; Kumura T; Hagihara K; Sakamoto E; Okamoto S; Hirose A; Aoyama Y; Yamamura R; Hayashi Y; Umemoto Y; Terada Y; Takeoka Y; Nakane T; Koh H; Hino M
Int J Hematol; 2009 Jun; 89(5):649-55. PubMed ID: 19449195
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study of intravenous injecting itraconazole as empirical antifungal therapy for patients with hematological malignancies].
Luo CW; DU X; Guo R; Weng JY; Lu ZS; Wu SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1000-4. PubMed ID: 22931672
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of itraconazole as empirical antifungal therapy in febrile neutropenic patients with hematologic malignancies: an open-lable, multicenter, observational trial in a Chinese cohort.
Cheng S; Zhou JF; Zou P; Huang XJ; Jin J; Shen ZX
Chin Med J (Engl); 2011 Nov; 124(22):3670-5. PubMed ID: 22340222
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.
Jeong SH; Kim DY; Jang JH; Mun YC; Choi CW; Kim SH; Kim JS; Park JS
Ann Hematol; 2016 Jan; 95(2):337-44. PubMed ID: 26596974
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Intravenous Itraconazole Versus Liposomal Amphotericin B as Empirical Antifungal Therapy in Hematological Malignancy with Persistent Fever and Neutropenia: Study Protocol for a Multicenter, Prospective, Randomized Non-inferiority Trial.
Saito AM; Yoshida I; Tanaka S; Sawamura M; Hidaka M; Yoshida S; Uike N; Kaneko Y; Miyazaki Y; Nagai H
Kurume Med J; 2021 Dec; 66(4):239-246. PubMed ID: 34544939
[TBL] [Abstract][Full Text] [Related]
6. Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Min WS; Shin WS
Korean J Intern Med; 2006 Sep; 21(3):165-72. PubMed ID: 17017665
[TBL] [Abstract][Full Text] [Related]
7. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.
Boogaerts M; Winston DJ; Bow EJ; Garber G; Reboli AC; Schwarer AP; Novitzky N; Boehme A; Chwetzoff E; De Beule K;
Ann Intern Med; 2001 Sep; 135(6):412-22. PubMed ID: 11560454
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of micafungin for febrile neutropenia in pediatric patients with hematological malignancies: a multicenter prospective study.
Kobayashi R; Suzuki N; Yoshida M; Iizuka S; Suzuki D; Sano H; Kudoh T
J Pediatr Hematol Oncol; 2013 Oct; 35(7):e276-9. PubMed ID: 23743960
[TBL] [Abstract][Full Text] [Related]
9. Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever.
Yoshida I; Saito AM; Tanaka S; Choi I; Hidaka M; Miyata Y; Inoue Y; Yamasaki S; Kagoo T; Iida H; Niimi H; Komeno T; Yoshida C; Tajima F; Yamamoto H; Takase K; Ueno H; Shimomura T; Sakai T; Nakashima Y; Yoshida C; Kubonishi S; Sunami K; Yoshida S; Sakurai A; Kaneko Y; Miyazaki Y; Nagai H
Mycoses; 2020 Aug; 63(8):794-801. PubMed ID: 32391919
[TBL] [Abstract][Full Text] [Related]
10. Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics.
Racil Z; Toskova M; Kocmanova I; Buresova L; Kouba M; Drgona L; Masarova L; Guman T; Tothova E; Gabzdilova J; Forsterova K; Haber J; Ziakova B; Bojtarova E; Rolencova M; Timilsina S; Cetkovsky P; Mayer J
Leuk Lymphoma; 2013 May; 54(5):1042-7. PubMed ID: 23088794
[TBL] [Abstract][Full Text] [Related]
11. The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea.
Kim JS; Cheong JW; Kim YK; Park J; Mun YC; Kang HJ; Yi HG; Lee JH; Kim YS; Ryoo HM; Kim SH; Kim HY; Kim JY; Lee DG; Kim HG; Kim H; Joo YD; Min YH
Ann Hematol; 2014 Jan; 93(1):33-42. PubMed ID: 23807252
[TBL] [Abstract][Full Text] [Related]
12. Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in Korea.
Kim SJ; Cheong JW; Min YH; Choi YJ; Lee DG; Lee JH; Yang DH; Lee SM; Kim SH; Kim YS; Kwak JY; Park J; Kim JY; Kim HG; Kim BS; Ryoo HM; Jang JH; Kim MK; Kang HJ; Cho IS; Mun YC; Jo DY; Kim HY; Park BB; Kim JS
J Korean Med Sci; 2014 Jan; 29(1):61-8. PubMed ID: 24431907
[TBL] [Abstract][Full Text] [Related]
13. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
[TBL] [Abstract][Full Text] [Related]
14. [Itraconazole capsules as antifungal prophylaxis for neutropenic patients with hematological malignancies from a single institution].
Toubai T; Tanaka J; Ota S; Kato N; Umehara S; Kahata K; Toyoshima N; Asaka M; Imamura M
Jpn J Antibiot; 2005 Dec; 58(6):507-17. PubMed ID: 16521343
[TBL] [Abstract][Full Text] [Related]
15. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy.
Schuler U; Bammer S; Aulitzky WE; Binder C; Böhme A; Egerer G; Sandherr M; Schwerdtfeger R; Silling G; Wandt H; Glasmacher A; Ehninger G
Onkologie; 2007 Apr; 30(4):185-91. PubMed ID: 17396041
[TBL] [Abstract][Full Text] [Related]
17. Itraconazole for invasive fungal infection with pediatric malignancies.
Kobayashi R; Suzuki D; Yasuda K; Kobayashi K
Pediatr Int; 2010 Oct; 52(5):707-10. PubMed ID: 20337979
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of low-dose amphotericin B lipid complex for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies.
Subirà M; Martino R; Sureda A; Altés A; Briones J; Brunet S; Sierra J
Methods Find Exp Clin Pharmacol; 2001 Nov; 23(9):505-10. PubMed ID: 11876025
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever.
Lee DG; Chae H; Yim DS; Park SH; Choi SM; Kim S; Choi JH; Yoo JH; Shin WS
J Clin Pharm Ther; 2009 Jun; 34(3):337-44. PubMed ID: 19646080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
